- Home
- MTA vs TLRY Comparison
MTA vs TLRY Comparison
Compare MTA & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTA | TLRY |
|---|---|---|
| Founded | 1983 | N/A |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.4M | 919.2M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MTA | TLRY |
|---|---|---|
| Price | $6.80 | $6.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $9.00 | ★ $72.33 |
| AVG Volume (30 Days) | 427.8K | ★ 5.9M |
| Earning Date | 05-15-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $81.63 | $8.79 |
| Revenue Next Year | $62.44 | $19.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $0.36 |
| 52 Week High | $9.25 | $15.70 |
Technical Indicators
Market Signals| Indicator | MTA | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 46.15 | 48.17 |
| Support Level | $6.48 | $6.13 |
| Resistance Level | $7.21 | $7.01 |
| Average True Range (ATR) | 0.32 | 0.54 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 45.39 | 13.26 |
Price Performance
Historical ComparisonAbout MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.